Novartis seeks European approval of cell therapy
[ZURICH] Swiss drugmaker Novartis said on Monday it submitted an application for its cell therapy Kymriah to be approved in Europe for two forms of blood cancer.
Novartis applied to the European Medicines Agency for the therapy to be used in children and young adults with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
The therapy, which Novartis expects to eventually top US$1 billion in annual sales, has been approved by US regulators in pediatric ALL and was submitted in the United States for adults with DLBCL last week.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action